How Much Does Astatine Cost?

Updated on July 27, 2026 | Written by Alec Pow
This article was researched using 8 sources. See our methodology and corrections policy.

Astatine-211 can reasonably be estimated at $5,000 to $30,000+ per research production run or shipment. The final cost depends on the radioactive activity requested, cyclotron time, bismuth target preparation, radiochemical separation, purity testing, specialized labor, regulatory documentation, radioactive packaging, and rapid transportation.

Using a published historical production estimate of approximately $30 per millicurie, astatine-211 has a theoretical activity-equivalent value of about $61.8 million per milligram, or roughly $61.8 billion per gram, at the moment of calibration. This is a calculated comparison rather than a realizable commodity price. Laboratories do not manufacture, store, or trade gram quantities of astatine because all known isotopes decay rapidly.

A practical research order may involve tens or hundreds of millicuries rather than a visible mass. At the historical $30-per-millicurie benchmark, 20 millicuries would represent about $600 in modeled isotope-production cost, while 130 millicuries would represent about $3,900. Modern institutional costs can be much higher once accelerator operations, staffing, separation chemistry, failed-run risk, quality control, shipping, and radiopharmaceutical preparation are included.

Article Highlights

• A practical astatine-211 production run may cost $5,000 to $30,000+ (at $30 per hour, earning that amount would take about 1 to 5.8 months of full-time work, before taxes).
• A historical academic model estimated approximately $30 per millicurie delivered to a remote user.
• The theoretical equivalent is about $61.8 million per milligram.
• The theoretical equivalent is about $61.8 billion per gram.
• Astatine-211 has a half-life of approximately 7.214 hours.
• Research quantities are ordered by radioactive activity rather than normal weight.
• A permanent collectible cube cannot contain a visible stock of real astatine.

Estimated Astatine Prices

Astatine cost measure	Estimated price	How to interpret it
Research production run or shipment	$5,000 to $30,000+ (about 1 to 5.8 months of full-time work at $30 per hour)	Modeled institutional total including production, processing, testing, and logistics
Historical At-211 production estimate	About $30 per millicurie	Published academic estimate rather than a guaranteed current quote
20-millicurie quantity	About $600	Historical activity-based equivalent before modern institutional overhead
130-millicurie production quantity	About $3,900	Historical activity-based equivalent before clinical preparation
Theoretical value per microgram	About $61,800	Calculated from specific activity and the $30-per-millicurie model
Theoretical value per milligram	About $61.8 million	Mathematical activity equivalent, not a tradable milligram price
Theoretical value per gram	About $61.8 billion	Hypothetical calculation only because a gram-scale product cannot be stocked
Finished At-211 radiopharmaceutical	Potentially tens of thousands of dollars per preparation	Includes targeting chemistry, testing, pharmacy work, and clinical handling

The most defensible buyer-facing number is the $5,000 to $30,000+ production-run estimate. It reflects the fact that an institution is paying for a coordinated nuclear-production and radiochemistry service rather than purchasing a piece of metal from a catalog.

The National Isotope Development Center states that astatine-211 can be ordered through the Department of Energy Isotope Program from Texas A&M University or the University of Washington. Current product information does not publish a universal price, so qualified customers must request a quote.

How the $61.8 Billion Figure Works

The theoretical mass value comes from the radioactive activity of astatine-211. One gram of At-211 contains approximately 2.85 × 10²¹ atoms. With a half-life of 7.214 hours, that hypothetical gram would have an initial activity of approximately 2.06 million curies, or 2.06 billion millicuries.

Multiplying 2.06 billion millicuries by the historical $30 (about 1 hour of work at $30 per hour)-per-millicurie estimate produces approximately $61.8 billion per gram. Dividing by 1,000 gives approximately $61.8 million per milligram. One microgram would have an equivalent value near $61,800.

This is valid as a mathematical activity comparison, but it is not a market transaction. No supplier produces a one-gram At-211 bar, and no buyer could preserve that gram. The isotope would begin decaying immediately, creating daughter products and losing half its At-211 atoms every 7.214 hours.

Why Earlier $5 Million Estimates Fail

The frequently repeated claim that astatine costs $5,000 per milligram or $5 million per gram does not identify an isotope, activity, calibration time, seller, transaction, or production method. It appears to be an internet estimate rather than a documented market rate.

It is also inconsistent with the specific activity of At-211. If the historical $30-per-millicurie model is used, the calculated activity equivalent is thousands of times higher than $5 million per gram. If actual institutional production costs are used, the buyer pays for a run or shipment rather than for a measurable gram.

The correct article approach is therefore to publish a useful run price, provide a clearly labeled theoretical mass value, and then explain why the mass value cannot be realized through normal buying and selling.

What a Research Run Includes

Astatine-211 production begins before the accelerator is turned on. The facility must schedule beam time, manufacture or prepare the bismuth target, inspect the target assembly, configure the cyclotron, assign trained personnel, and coordinate the receiving laboratory’s timetable.

A representative institutional cost stack may include:

• $4,000 to $12,000 for accelerator reservation, technical labor, and irradiation
• $500 to $2,500 for the bismuth target, backing plate, preparation, and handling
• $2,000 to $7,500 for radiochemical separation and purification
• $1,000 to $4,000 for activity measurement, purity testing, and documentation
• $500 to $3,000 for radioactive packaging and rapid transportation
• $1,000 to $5,000+ for project administration, radiation safety, and specialized support

These modeled components produce a broad total near $9,000 to $34,000+, supporting the article’s rounded headline estimate of $5,000 to $30,000+. An institution may pay less when infrastructure is grant-funded or services are subsidized, while a complex clinical-grade preparation can cost considerably more.

The Historical $30-per-mCi Estimate

A widely cited 2011 production analysis described approximately $400 per hour in Duke University cyclotron charges and about $75 for a bismuth target and aluminum backing plate. The researchers reported production of 150 to 175 millicuries after a four-hour bombardment.

The initial production calculation came to approximately $10 per millicurie. After allowing for a 67% isolation yield and one half-life of processing and physical decay, the authors estimated approximately $30 per millicurie delivered to a remote user.

The full paper, Astatine-211: Production and Availability, provides an important historical benchmark. It does not establish a 2026 retail list price. Accelerator charges, wages, compliance costs, transportation, quality requirements, and clinical standards have changed since the calculation was published.

Activity Matters More Than Weight

Astatine-211 is supplied according to radioactive activity, chemical form, purity, calibration time, and destination. Activity is measured in becquerels, megabecquerels, curies, or millicuries. One curie equals 37 billion radioactive decays per second.

A quote for 50 millicuries is incomplete unless it states when those 50 millicuries apply. It may refer to the end of bombardment, end of purification, dispatch time, arrival, or planned administration. Because the isotope decays continuously, those amounts can differ greatly.

This resembles the production and handling costs behind nuclear imaging materials. Readers comparing the broader medical cost structure can review current PET scan prices, where the radiotracer is only one part of the patient’s total bill.

Decay Raises the Delivered Cost

The DOE Isotope Program gives astatine-211 a half-life of 7.214 hours. After one half-life, 50% of the starting activity remains. After two half-lives, 25% remains. After three, only 12.5% remains.

Suppose a producer finishes purification with 100 millicuries. After 4 hours, approximately 68 millicuries remain. After 8 hours, about 46 millicuries remain. After 12 hours, the shipment has roughly 32 millicuries. After 24 hours, less than 10 millicuries remain.

This decay creates a hidden cost. The producer may need to manufacture substantially more activity than the receiving laboratory ultimately uses. A delayed courier, missed flight, failed quality test, equipment malfunction, or postponed patient appointment can destroy much of the practical value of an otherwise successful run.

How Astatine-211 Is Produced

Medically useful At-211 is usually produced by bombarding natural bismuth-209 with alpha particles in a cyclotron. The reaction is written as ²⁰⁹Bi(α,2n)²¹¹At. The bismuth nucleus absorbs the alpha particle and releases two neutrons.

The Department of Energy’s production description explains that isolation from the irradiated bismuth target requires specialized radiochemical processing. The work may occur in a radiological glovebox or another controlled system.

Many hospital cyclotrons produce common imaging isotopes using proton beams. They cannot automatically make At-211 because the process requires a suitable alpha-particle beam, target station, separation laboratory, and appropriately licensed staff.

Limited Production Network

The Department of Energy reported in December 2024 that only five centers in the United States were capable of producing At-211. The limited network makes regional coordination important because the isotope cannot tolerate long storage or slow transportation.

A February 2026 At-211 product information sheet identifies the University of Washington and Texas A&M University as available DOE network producers. The document lists a 7.214-hour half-life and requires prospective users to coordinate production and delivery.

Production capabilities are expanding, but each cyclotron has limited beam time and batch capacity. More regional facilities could reduce transport losses and improve availability without creating a stable bulk market.

Raw Isotope vs Finished Treatment

Raw At-211 is not a complete cancer treatment. Researchers must attach it to an antibody, peptide, or small molecule that targets particular cells. The labeled compound must then be purified, formulated, tested, and prepared under the relevant research or clinical standards.

A finished investigational radiopharmaceutical may require:

• Manufacturing or obtaining the targeting molecule
• Radiolabeling and chemical purification
• Testing for identity, purity, activity, sterility, and endotoxins
• Clinical pharmacy preparation
• Patient-specific dose calculation
• Radiation-safety supervision
• Administration, imaging, monitoring, and follow-up

Those services can move the cost of one preparation into the tens of thousands of dollars, even when the modeled intrinsic isotope portion is only several thousand. The broader treatment expense can be compared with the cost categories described in ThePricer’s guide to chemotherapy costs.

Current Medical Uses

Astatine-211 is being studied for targeted alpha therapy. Alpha particles deposit high energy over a very short tissue range. When the isotope remains attached to a targeting molecule, this may allow researchers to damage selected cancer cells while limiting radiation farther from the target.

At-211 is not an approved universal cancer therapy. It is an investigational component in laboratory studies and clinical trials involving blood cancers, ovarian cancer, brain tumors, prostate cancer, multiple myeloma, and other diseases.

ClinicalTrials.gov lists an At-211 antibody study for patients with high-risk leukemia and related blood disorders before donor stem-cell transplantation. Another registered study evaluates an At-211 PSMA-targeting drug for castration-resistant prostate cancer.

A registered clinical trial does not prove approval, safety, effectiveness, or commercial availability. Patients cannot purchase astatine independently and bring it to a clinic.

Chemistry Adds Expense

Astatine chemistry is difficult because researchers work with extremely small numbers of atoms at high radioactive activity. The material can adsorb to surfaces, change oxidation state, form volatile species, and be affected by radiolysis.

The bond connecting At-211 to a targeting molecule must remain stable long enough for the compound to reach the intended cells. Released astatine may distribute elsewhere in the body and reduce treatment specificity.

The Department of Energy reported in 2025 on improved understanding of astatine bonding relevant to radiopharmaceutical development. Better chemistry can improve usable yield, but it cannot change the isotope’s nuclear half-life.

Safety and Waste Costs

At-211 must be handled by qualified institutions with radioactive-material authorization, trained workers, contamination monitoring, controlled work areas, and documented procedures. Important concerns include internal contamination, volatile compounds, contaminated surfaces, daughter products, and mistakes during transfer or labeling.

Facilities may use gloveboxes, fume hoods, remote tools, syringe shields, dosimeters, air monitoring, restricted access, and specialized survey equipment. The correct shielding depends on the activity, chemical form, procedure, and secondary radiation. Lead is not an automatic universal solution.

The isotope’s short half-life can simplify final waste management. Authorized facilities may hold suitable waste for decay until it meets release or disposal criteria. Storage, surveys, documentation, containers, and staff time still add to the production cost.

Why Display Cubes Are Not Real Astatine

Periodic-table retailers sometimes sell an astatine-themed cube for hundreds or thousands of dollars. A permanent display cube cannot contain a visible, lasting stock of real astatine. After ten At-211 half-lives, approximately three days, less than 0.1% of the starting isotope remains.

The cube may contain a label, image, substitute material, symbolic insert, or empty position representing element 85. Its price reflects design, manufacturing, marketing, and collectible scarcity rather than the value of elemental astatine.

A buyer should treat a $2,400 astatine cube as a novelty collectible unless the seller provides legally valid isotope documentation, activity, isotope number, calibration time, packaging classification, and transfer authorization. A normal consumer display product will not meet those conditions.

Natural Astatine Has No Mine Price

Trace astatine forms naturally within radioactive decay chains. It disappears so quickly that it cannot accumulate into a commercial ore body. Estimates that less than one gram exists naturally in Earth’s crust refer to the amount present at a particular moment, not to annual production.

No company mines astatine-bearing rock and sells refined At by the ounce. Natural scarcity helps explain its scientific interest, but it does not produce a normal market price without a stable product, repeatable quantity, storage life, and network of transactions.

Three Cost Scenarios

Small research shipment: A laboratory requests 20 millicuries. At the historical $30-per-millicurie benchmark, the isotope equivalent is $600. Adding $5,000 for production access, $2,500 for separation and testing, and $1,500 for packaging and transport produces a modeled total of $9,600.

Regional clinical research run: A facility produces 130 millicuries. The historical activity equivalent is $3,900. Accelerator operations, clinical-grade processing, quality control, staff, and rapid delivery add $16,000, producing an illustrative total of $19,900 before drug labeling and patient care.

Finished investigational preparation: Production and delivery cost $18,000. Radiolabeling, sterile preparation, testing, dosimetry, pharmacy work, and clinical staffing add $22,000. The complete preparation reaches $40,000. This is a modeled example rather than a published treatment price.

When a Price Claim Is Credible

A useful astatine quote identifies:

• The isotope, usually astatine-211
• The requested activity in millicuries or megabecquerels
• The exact calibration date and time
• The chemical form and solvent
• Purity and testing requirements
• The production and delivery schedule
• Packaging, shipping, and documentation
• Whether radiolabeling is included

A price claim is weak when it:

• Offers grams or milligrams without an isotope number
• Omits activity and calibration time
• Treats the material as a stable collectible
• Claims a permanent investment value
• Confuses a production-cost model with a current supplier quote
• Ignores decay during processing and delivery

What We Verified

• Checked current availability through the National Isotope Development Center.
• Confirmed the 7.214-hour At-211 half-life through the 2026 DOE product sheet.
• Verified the historical $30-per-millicurie calculation through the published production study.
• Calculated the $61.8 million-per-milligram theoretical activity equivalent from At-211 specific activity.
• Cross-referenced active medical research through ClinicalTrials.gov and DOE sources.

Answers to Common Questions

How much does astatine cost?

A practical astatine-211 research production run or shipment can be estimated at $5,000 to $30,000+. Actual suppliers provide project-specific quotes.

How much is one milligram of astatine worth?

Using the historical $30-per-millicurie estimate, one milligram of At-211 has a theoretical activity-equivalent value of about $61.8 million. It is not a realizable retail price.

How much is one gram of astatine worth?

The same calculation produces approximately $61.8 billion per gram. A gram cannot be manufactured, preserved, and traded as a normal product.

Can an individual buy astatine?

Not through an ordinary consumer transaction. At-211 is supplied to qualified institutions through regulated isotope-production and research programs.

Does an astatine display cube contain real astatine?

A permanent consumer display cube cannot contain a lasting visible sample. It is a representation or novelty product rather than a stock of astatine.

Is astatine-211 used to treat cancer?

At-211 is being studied in targeted alpha therapies and clinical trials. It is not a generally available standalone cancer treatment.